公开(公告)号：US20190256572A1

公开(公告)日：2019-08-22

申请号：US16403038

申请日：2019-05-03

Applicant: Immatics Biotechnologies GmbH

Inventor： Leonie ALTEN ,  Dominik MAURER ,  Sebastian BUNK ,  Claudia WAGNER ,  Mathias FERBER

IPC: C07K14/725 ,  C07K16/30

Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular against Preferentially Expressed Antigen of Melanoma (PRAME). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

公开(公告)号：US20220098270A1

公开(公告)日：2022-03-31

申请号：US17553017

申请日：2021-12-16

Applicant: Immatics Biotechnologies GmbH

Inventor： Leonie ALTEN ,  Dominik MAURER ,  Sebastian BUNK ,  Claudia WAGNER ,  Mathias FERBER

IPC: C07K14/725 ,  C07K14/47 ,  A61K35/17 ,  C12N5/0783 ,  C12N5/10 ,  A61K35/12

Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular against Preferentially Expressed Antigen of Melanoma (PRAME). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

公开(公告)号：US20250163124A1

公开(公告)日：2025-05-22

申请号：US19024104

申请日：2025-01-16

Applicant: Immatics Biotechnologies GmbH

Inventor： Sebastian BUNK ,  Dominik MAURER ,  Jens FRITSCHE ,  Claudia WAGNER ,  Leonie ALTEN ,  Franziska HOFFGAARD ,  Mathias FERBER

IPC: C07K14/725 ,  A61K35/17 ,  C12N5/0783 ,  C12N15/09

Abstract: The present invention relates to modified T cell receptor (TCR) α or β chains, or heterodimers comprising the same, wherein in the variable domain of said modified α or β chain, an amino acid at position 44 according to the IMGT numbering is substituted by another suitable amino acid in order to improve pairing of desired chains.

公开(公告)号：US20210380659A1

公开(公告)日：2021-12-09

申请号：US17354555

申请日：2021-06-22

Applicant: Immatics Biotechnologies GmbH

Inventor： Sebastian BUNK ,  Dominik MAURER ,  Jens FRITSCHE ,  Claudia WAGNER ,  Leonie ALTEN ,  Franziska HOFFGAARD ,  Mathias FERBER

IPC: C07K14/725 ,  C12N15/09 ,  A61K35/17 ,  C12N5/0783

Abstract: The present invention relates to modified T cell receptor (TCR) α or β chains, or heterodimers comprising the same, wherein in the variable domain of said modified α or β chain, an amino acid at position 44 according to the IMGT numbering is substituted by another suitable amino acid in order to improve pairing of desired chains.